Alternatives to Tempus AI

AI-powered precision testing for patient identification in clinics and clinical trials.

Digital pathology imaging technology and AI-driven precision pathology software.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Leveraging the adaptive immune system to diagnose and treat disease.

Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.

AI-powered spatial biology platform for precision medicine and drug development.

Phenomics-driven AI company translating disease biology into precision medicine discoveries.

Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

Comprehensive whole-genome monitoring for cancer recurrence and progression.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Developing engineered biologics to harness the immune system for disease treatment.

AI-driven diagnostics company predicting cancer treatment response from pathology slides.

MeMed develops and commercializes host immune response diagnostic solutions to address complex clinical dilemmas and improve patient outcomes.

Lunit is a medical AI company developing AI-powered solutions for cancer diagnostics and therapeutics.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Personalized nutrition and metabolic health platform using gut microbiome and AI.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.